Even so, a vaccine would still take more than a year to develop, he said.
Gershoni, who has studied the family of viruses for 15 years, said that he was recently granted a patent by the United States Patent and Trademark Office for his vaccine design. He explained that the vaccine intends to target the virus’s Receptor Binding Motif (RBM), a critical weak point which allows the virus to attach itself and infect a target cell.
Comments are closed.